Value investing rests on a simple premise: buy shares for less than they are worth and let time close the gap between price and intrinsic value. The challenge is finding candidates that are genuinely undervalued rather than merely cheap for a reason. The Decent Value screen addresses that problem by combining valuation filters with minimum quality requirements, selecting stocks that score well on valuation while still showing decent profitability, health, and growth. One name that currently qualifies is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT).
What the Decent Value screen demands
The screen is designed for investors who want value without sacrificing fundamental quality. Rather than chasing the deepest discounts, it looks for a balanced profile across four areas:
- Valuation: the stock must be attractively priced relative to earnings, cash flow, or assets
- Profitability: the company should generate solid returns, not just report low multiples
- Health: the balance sheet must be able to support the business through cycles
- Growth: some forward momentum is expected, so value does not turn into a value trap
Arcutis clears each of those hurdles, with an overall fundamental rating of 6 out of 10 from ChartMill. The most interesting combination sits in the growth and value categories, where the company scores 8 and 7 out of 10 respectively.
Valuation: growth at a reasonable price
The valuation case for Arcutis is best understood relative to its industry rather than in absolute terms. The trailing price-to-earnings ratio stands at 119.43, which looks expensive on its own, but that figure has to be weighed against the fact that 90.63% of its biotechnology peers are valued more expensively. The forward P/E of 23.65 is far more moderate, and it sits well below the industry average of 33.67.
Other multiples reinforce the picture:
- Enterprise value to EBITDA: cheaper than 89.84% of industry peers
- Price to free cash flow: cheaper than 90.63% of industry peers
- PEG ratio (non-GAAP): low enough to indicate a rather cheap valuation once growth is factored in
Part of the reason the valuation looks reasonable is that earnings are expected to grow by 149.32% in the coming years. That expected growth, combined with a decent profitability rating, helps justify the multiple and supports the view that the stock is undervalued relative to its forward potential. Investors who want to review the full fundamental breakdown can check the detailed fundamental analysis report.
Growth: strong momentum across the board
The growth component is where Arcutis stands out most clearly. The company has shown:
- Earnings per share growth of 128.00% over the past year
- Revenue growth of 76.11% in the past year
- Average revenue growth of 367.11% over the past several years
- Expected EPS growth of 90.20% per year going forward
- Expected revenue growth of 25.10% per year going forward
That kind of expansion is exactly what the Decent Value screen wants to see. A low valuation without growth can easily become a value trap, but strong fundamental momentum reduces that risk and increases the chance that the market will eventually re-rate the shares.
Profitability and financial health: acceptable with room to improve
Arcutis scores 6 out of 10 on both profitability and health, which is a neutral evaluation but still sufficient for the screen. On profitability, the company has produced positive earnings and positive operating cash flow over the past year, a notable achievement for a biotechnology company. The return ratios are actually among the best in its peer group:
- Return on equity: 12.93%, outperforming 93.16% of the industry
- Return on invested capital: 8.25%, outperforming 92.97% of the industry
- Return on assets: 5.84%, outperforming 91.80% of the industry
- Operating margin: 7.38%, outperforming 90.63% of the industry
- Gross margin: 91.14%, outperforming 92.38% of the industry
On the health side, the balance sheet is solid but not flawless. The Altman-Z score of 5.71 indicates a low risk of bankruptcy, and the debt-to-FCF ratio of 2.78 means the company could pay off all of its debt in under three years. The current ratio of 2.92 and quick ratio of 2.67 both point to adequate short-term liquidity. The main negatives are that ROIC is currently below the cost of capital and the share count has increased over time, which dilutes existing holders.
These metrics matter for the Decent Value strategy because they separate temporary undervaluation from structural weakness. A stock can be cheap because the market is pessimistic, or it can be cheap because the business is deteriorating. The combination of strong growth, industry-leading margins, and a manageable balance sheet suggests that Arcutis belongs in the former camp.
Risks to consider
No value thesis comes without caveats. Arcutis does not pay a dividend, so income-oriented investors will not find it suitable. The company also has a history of negative net income in prior years, and its valuation still depends on the expected growth materializing. If the pipeline disappoints or revenue growth slows more sharply than projected, the stock could remain cheap for an extended period.
Other ChartMill screens reinforce the thesis
Arcutis also appears on other ChartMill screens that reward a similar mix of growth and financial quality. The Highest Analyst Upside screen flags ARQT based on price targets implying meaningful upside from the current price, adding an external check on the valuation angle. On the growth side, the Fastest Growing Stocks screen picks out the stock for strong recent growth in both earnings and sales, while the High EPS Growth Stocks screen highlights it as profitable, financially healthy, and showing strong per-share earnings momentum. Together, these screens support the idea that Arcutis is not a beaten-down value trap, but a growing business still trading below analyst expectations.
Finding more stocks like this
For investors who want to apply the same methodology more broadly, the Decent Value screen can be used to identify other stocks that combine attractive valuations with decent profitability, health, and growth. It offers a practical starting point for value investors who want to avoid the trap of buying cheap companies that never recover.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum
Value investing rests on a simple premise: buy shares for less than they are worth and let time close the gap between price and intrinsic value. The challenge is finding candidates that are genuinely undervalued rather than merely cheap for a reason. The Decent Value screen addresses that problem by combining valuation filters with minimum quality requirements, selecting stocks that score well on valuation while still showing decent profitability, health, and growth. One name that currently qualifies is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT).
What the Decent Value screen demands
The screen is designed for investors who want value without sacrificing fundamental quality. Rather than chasing the deepest discounts, it looks for a balanced profile across four areas:
Arcutis clears each of those hurdles, with an overall fundamental rating of 6 out of 10 from ChartMill. The most interesting combination sits in the growth and value categories, where the company scores 8 and 7 out of 10 respectively.
Valuation: growth at a reasonable price
The valuation case for Arcutis is best understood relative to its industry rather than in absolute terms. The trailing price-to-earnings ratio stands at 119.43, which looks expensive on its own, but that figure has to be weighed against the fact that 90.63% of its biotechnology peers are valued more expensively. The forward P/E of 23.65 is far more moderate, and it sits well below the industry average of 33.67.
Other multiples reinforce the picture:
Part of the reason the valuation looks reasonable is that earnings are expected to grow by 149.32% in the coming years. That expected growth, combined with a decent profitability rating, helps justify the multiple and supports the view that the stock is undervalued relative to its forward potential. Investors who want to review the full fundamental breakdown can check the detailed fundamental analysis report.
Growth: strong momentum across the board
The growth component is where Arcutis stands out most clearly. The company has shown:
That kind of expansion is exactly what the Decent Value screen wants to see. A low valuation without growth can easily become a value trap, but strong fundamental momentum reduces that risk and increases the chance that the market will eventually re-rate the shares.
Profitability and financial health: acceptable with room to improve
Arcutis scores 6 out of 10 on both profitability and health, which is a neutral evaluation but still sufficient for the screen. On profitability, the company has produced positive earnings and positive operating cash flow over the past year, a notable achievement for a biotechnology company. The return ratios are actually among the best in its peer group:
On the health side, the balance sheet is solid but not flawless. The Altman-Z score of 5.71 indicates a low risk of bankruptcy, and the debt-to-FCF ratio of 2.78 means the company could pay off all of its debt in under three years. The current ratio of 2.92 and quick ratio of 2.67 both point to adequate short-term liquidity. The main negatives are that ROIC is currently below the cost of capital and the share count has increased over time, which dilutes existing holders.
These metrics matter for the Decent Value strategy because they separate temporary undervaluation from structural weakness. A stock can be cheap because the market is pessimistic, or it can be cheap because the business is deteriorating. The combination of strong growth, industry-leading margins, and a manageable balance sheet suggests that Arcutis belongs in the former camp.
Risks to consider
No value thesis comes without caveats. Arcutis does not pay a dividend, so income-oriented investors will not find it suitable. The company also has a history of negative net income in prior years, and its valuation still depends on the expected growth materializing. If the pipeline disappoints or revenue growth slows more sharply than projected, the stock could remain cheap for an extended period.
Other ChartMill screens reinforce the thesis
Arcutis also appears on other ChartMill screens that reward a similar mix of growth and financial quality. The Highest Analyst Upside screen flags ARQT based on price targets implying meaningful upside from the current price, adding an external check on the valuation angle. On the growth side, the Fastest Growing Stocks screen picks out the stock for strong recent growth in both earnings and sales, while the High EPS Growth Stocks screen highlights it as profitable, financially healthy, and showing strong per-share earnings momentum. Together, these screens support the idea that Arcutis is not a beaten-down value trap, but a growing business still trading below analyst expectations.
Finding more stocks like this
For investors who want to apply the same methodology more broadly, the Decent Value screen can be used to identify other stocks that combine attractive valuations with decent profitability, health, and growth. It offers a practical starting point for value investors who want to avoid the trap of buying cheap companies that never recover.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »